<table>
<thead>
<tr>
<th>Participant ID</th>
<th>Date AE Reported to Site</th>
</tr>
</thead>
<tbody>
<tr>
<td>Site Number</td>
<td>Participant Number Chk</td>
</tr>
<tr>
<td>dd MMM yy</td>
<td>dd MMM yy</td>
</tr>
</tbody>
</table>

### Adverse Experience Log

1. **Adverse Experience (AE)** Record diagnosis (in English) if available. Include anatomical location, if applicable.

2. **Onset date**

   - dd
   - MMM
   - yy

3. **At which visit was this AE first reported?**

   - visit code

4. **Severity**

   - Grade 1—mild
   - Grade 2—moderate
   - Grade 3—severe
   - Grade 4—potentially life-threatening
   - Grade 5—death

5. **Relationship to study product**

   - related
   - not related

   Record rationale or alternative etiology in Comments.

6. **Study product administration**

   - no change
   - held
   - permanently discontinued
   - N/A

7. **Status or Outcome of AE**

   - continuing
   - resolved
   - death
   - severity/frequency increased (report as new AE)
   - continuing at end of study participation

    **7a. Status/Outcome Date**

    - dd
    - MMM
    - yy

    If severity/frequency increased, record the new AE page #

8. **Treatment**

   Mark “none” or all that apply.

   - none
   - new/prolonged hospitalization Comment below.
   - medication(s) (Report on CM)
   - procedure/surgery Comment below.
   - other, specify Comment below.

   If none, go to item 9.

9. **Is this an SAE according to ICH guidelines?**

   - yes
   - no

10. **Has or will this AE be reported as an EAE?**

    - yes
    - no

11. **Was this AE a worsening of a pre-existing condition?**

    - yes
    - no

Comments:

---

Version 1.0, 01-APR-15

Staff Initials/Date
Purpose:
To document any Adverse Experience (AE) reported by the participant or clinically observed as defined by the protocol.

General Instructions:
Do not record a condition as an AE if it existed at enrollment as a pre-existing condition, unless it increases in severity or frequency. If a cluster of symptoms reported on separate AE Log pages is later attributed to a single diagnosis, change the earliest reported symptom to the final diagnosis. In addition, mark the AE Log pages for the other symptoms with the words “Delete due to diagnosis on AE page #” (specify page number of diagnosis AE).

Item-specific Instructions:

<table>
<thead>
<tr>
<th>Page #</th>
<th>Number pages sequentially throughout the study, starting with 001. Do not repeat page numbers. Do not renumber any AE Log pages after faxing, unless instructed by DF/Net.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Item 1</td>
<td>Whenever possible, provide a diagnosis instead of listing a cluster of symptoms. If no diagnosis is identified, each symptom must be recorded on a separate page of the AE Log. If an abnormal lab value is reported, record the lab assay with the direction (i.e., increased or decreased) of the abnormality. For example, “decreased hematocrit” or “increased ALT.”</td>
</tr>
<tr>
<td>Item 2</td>
<td>At minimum, month and year are required. Record one of the following, as appropriate: the date on which the participant reports first experiencing the AE; if the AE is discovered during the study visit exam, record the date of the study visit exam; if the AE is an abnormal lab result, record the date on which the specimen was collected.</td>
</tr>
<tr>
<td>Item 4</td>
<td>To grade the severity of an AE, consult the Division of AIDS (DAIDS) Table for Grading the Severity of Adult and Pediatric Adverse Experiences and the Addendum 1 (Female Genital Grading Table for Use in Microbicide Studies).</td>
</tr>
<tr>
<td>Item 5</td>
<td>Mark the assessment of the relationship between the AE and the study agent. Mark “related” if there is a reasonable possibility that the AE may be related to the study agent. Mark “not related” if there is not a reasonable possibility that the AE is related to the study agent. Record an alternative etiology, diagnosis, or explanation in Comments. For more information, refer to the Manual for Expedited Reporting of Adverse Events to DAIDS, Version 2.</td>
</tr>
<tr>
<td>Item 6</td>
<td>no change: Mark if the participant is expected to continue to use study product and the AE does NOT result in a study product hold or permanent discontinuation. held: Mark if the AE results in a study product hold. If multiple AEs are reported at the same visit, mark “held” for the AE(s) that contributed to the product hold. permanently discontinued: Mark if the AE results in permanent discontinuation of study product. If multiple AEs are reported at the same visit, mark “permanently discontinued” for the AE(s) that contributed to the permanent discontinuation. N/A (not applicable): Mark if the AE occurred after the participant had completed all administration of the study product, or the study product is held or permanently discontinued for a different AE or other reason, or the AE is grade 5-death.</td>
</tr>
<tr>
<td>Item 7</td>
<td>continuing: AE is continuing at the time it is reported. continuing at end of study participation: Mark this box whenever an AE is continuing at the time of participant study termination. resolved: Condition is no longer present, or returned to the pre-enrollment severity/frequency. If a participant is taking a medication to control an AE that arose during study participation, it is not considered resolved. death: Mark only if the severity of this AE is grade 6. Any other AEs continuing at the time of death should be changed to “continuing at end of study participation.” severity/frequency increased: If an AE increases in severity or frequency after it has been reported on the AE Log, line through the “continuing” box previously marked and mark “severity/frequency increased.” Record the date of increase in the “Status/Outcome Date.” Report the increase in severity or frequency as a new AE and record new AE Page # in space provided. If a new AE Page # is completed, an AE Log page with corresponding AE number must be received. For this new AE, the “Onset Date” will be the date that the severity or frequency increased. Update EAE form if applicable. Note that decreases in severity should not be recorded as new AEs.</td>
</tr>
<tr>
<td>Item 7a</td>
<td>At minimum, month and year are required. Record one of the following as appropriate: the date on which the participant no longer experienced the AE, or the date of the study visit or specimen collection at which the change in status/outcome is first noted.</td>
</tr>
<tr>
<td>Item 8</td>
<td>Indicate all treatments administered for this AE, including treatment provided by a health care professional and participant self-treatment. Do not indicate treatments that were clinically indicated or prescribed but not administered.</td>
</tr>
<tr>
<td>Items 9–10</td>
<td>For questions about ICH guidelines and EAE reporting, refer to the Manual for Expedited Reporting of Adverse Events to DAIDS, Version 2.</td>
</tr>
</tbody>
</table>
# Concomitant Medications Log (CM)

## Participant Information
- **Participant ID**
  - Site Number
  - Participant Number
  - Chk

## No Medications Taken
- **No medications taken at Screening/Enrollment**
  - **Staff Initials/Date**
- **No medications taken throughout study**
  - **Staff Initials/Date**

## End of Form
- **End of form. Submit to DF/Net.**

## Concomitant Medications Log

<table>
<thead>
<tr>
<th>Medication Name</th>
<th>Staff Initials/Log Entry Date</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>1</strong> Medication Name</td>
<td></td>
</tr>
<tr>
<td><strong>Indication</strong></td>
<td></td>
</tr>
<tr>
<td><strong>Date Started</strong></td>
<td><strong>Date Stopped</strong></td>
</tr>
<tr>
<td>dd</td>
<td>MMM</td>
</tr>
<tr>
<td><strong>Continuous at end of study</strong></td>
<td></td>
</tr>
<tr>
<td><strong>Dose/Units</strong></td>
<td><strong>Frequency</strong></td>
</tr>
<tr>
<td>pm</td>
<td>qd</td>
</tr>
<tr>
<td><strong>Route</strong></td>
<td></td>
</tr>
<tr>
<td>PO</td>
<td>IM</td>
</tr>
<tr>
<td><strong>Taken for a reported AE?</strong></td>
<td></td>
</tr>
<tr>
<td>yes</td>
<td>no</td>
</tr>
<tr>
<td><strong>AE Log page(s)</strong></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Medication Name</th>
<th>Staff Initials/Log Entry Date</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>2</strong> Medication Name</td>
<td></td>
</tr>
<tr>
<td><strong>Indication</strong></td>
<td></td>
</tr>
<tr>
<td><strong>Date Started</strong></td>
<td><strong>Date Stopped</strong></td>
</tr>
<tr>
<td>dd</td>
<td>MMM</td>
</tr>
<tr>
<td><strong>Continuous at end of study</strong></td>
<td></td>
</tr>
<tr>
<td><strong>Dose/Units</strong></td>
<td><strong>Frequency</strong></td>
</tr>
<tr>
<td>pm</td>
<td>qd</td>
</tr>
<tr>
<td><strong>Route</strong></td>
<td></td>
</tr>
<tr>
<td>PO</td>
<td>IM</td>
</tr>
<tr>
<td><strong>Taken for a reported AE?</strong></td>
<td></td>
</tr>
<tr>
<td>yes</td>
<td>no</td>
</tr>
<tr>
<td><strong>AE Log page(s)</strong></td>
<td></td>
</tr>
</tbody>
</table>

- **Note:** Number pages sequentially (01, 02, 03) for each participant.
- **Version 2.0, 13-MAY-15**
- **Page #**

- **No medications taken at Screening/Enrollment.**
  - **Staff Initials/Date**
- **No medications taken throughout study.**
  - **Staff Initials/Date**

- **End of form. Submit to DF/Net.**

- **Page #**

- **No medications taken at Screening/Enrollment.**
  - **Staff Initials/Date**
- **No medications taken throughout study.**
  - **Staff Initials/Date**

- **End of form. Submit to DF/Net.**

- **Page #**

- **No medications taken at Screening/Enrollment.**
  - **Staff Initials/Date**
- **No medications taken throughout study.**
  - **Staff Initials/Date**

- **End of form. Submit to DF/Net.**

- **Page #**

- **No medications taken at Screening/Enrollment.**
  - **Staff Initials/Date**
- **No medications taken throughout study.**
  - **Staff Initials/Date**

- **End of form. Submit to DF/Net.**

- **Page #**

- **No medications taken at Screening/Enrollment.**
  - **Staff Initials/Date**
- **No medications taken throughout study.**
  - **Staff Initials/Date**

- **End of form. Submit to DF/Net.**

- **Page #**

- **No medications taken at Screening/Enrollment.**
  - **Staff Initials/Date**
- **No medications taken throughout study.**
  - **Staff Initials/Date**

- **End of form. Submit to DF/Net.**

- **Page #**

- **No medications taken at Screening/Enrollment.**
  - **Staff Initials/Date**
- **No medications taken throughout study.**
  - **Staff Initials/Date**

- **End of form. Submit to DF/Net.**

- **Page #**

- **No medications taken at Screening/Enrollment.**
  - **Staff Initials/Date**
- **No medications taken throughout study.**
  - **Staff Initials/Date**

- **End of form. Submit to DF/Net.**

- **Page #**

- **No medications taken at Screening/Enrollment.**
  - **Staff Initials/Date**
- **No medications taken throughout study.**
  - **Staff Initials/Date**

- **End of form. Submit to DF/Net.**

- **Page #**

- **No medications taken at Screening/Enrollment.**
  - **Staff Initials/Date**
- **No medications taken throughout study.**
  - **Staff Initials/Date**

- **End of form. Submit to DF/Net.**

- **Page #**

- **No medications taken at Screening/Enrollment.**
  - **Staff Initials/Date**
- **No medications taken throughout study.**
  - **Staff Initials/Date**

- **End of form. Submit to DF/Net.**

- **Page #**

- **No medications taken at Screening/Enrollment.**
  - **Staff Initials/Date**
- **No medications taken throughout study.**
  - **Staff Initials/Date**

- **End of form. Submit to DF/Net.**

- **Page #**

- **No medications taken at Screening/Enrollment.**
  - **Staff Initials/Date**
- **No medications taken throughout study.**
  - **Staff Initials/Date**

- **End of form. Submit to DF/Net.**

- **Page #**

- **No medications taken at Screening/Enrollment.**
  - **Staff Initials/Date**
- **No medications taken throughout study.**
  - **Staff Initials/Date**

- **End of form. Submit to DF/Net.**

- **Page #**

- **No medications taken at Screening/Enrollment.**
  - **Staff Initials/Date**
- **No medications taken throughout study.**
  - **Staff Initials/Date**

- **End of form. Submit to DF/Net.**

- **Page #**

- **No medications taken at Screening/Enrollment.**
  - **Staff Initials/Date**
- **No medications taken throughout study.**
  - **Staff Initials/Date**

- **End of form. Submit to DF/Net.**

- **Page #**

- **No medications taken at Screening/Enrollment.**
  - **Staff Initials/Date**
- **No medications taken throughout study.**
  - **Staff Initials/Date**

- **End of form. Submit to DF/Net.**

- **Page #**

- **No medications taken at Screening/Enrollment.**
  - **Staff Initials/Date**
- **No medications taken throughout study.**
  - **Staff Initials/Date**

- **End of form. Submit to DF/Net.**

- **Page #**

- **No medications taken at Screening/Enrollment.**
  - **Staff Initials/Date**
- **No medications taken throughout study.**
  - **Staff Initials/Date**

- **End of form. Submit to DF/Net.**

- **Page #**

- **No medications taken at Screening/Enrollment.**
  - **Staff Initials/Date**
- **No medications taken throughout study.**
  - **Staff Initials/Date**

- **End of form. Submit to DF/Net.**

- **Page #**

- **No medications taken at Screening/Enrollment.**
  - **Staff Initials/Date**
- **No medications taken throughout study.**
  - **Staff Initials/Date**

- **End of form. Submit to DF/Net.**

- **Page #**

- **No medications taken at Screening/Enrollment.**
  - **Staff Initials/Date**
- **No medications taken throughout study.**
  - **Staff Initials/Date**

- **End of form. Submit to DF/Net.**

- **Page #**

- **No medications taken at Screening/Enrollment.**
  - **Staff Initials/Date**
- **No medications taken throughout study.**
  - **Staff Initials/Date**

- **End of form. Submit to DF/Net.**

- **Page #**

- **No medications taken at Screening/Enrollment.**
  - **Staff Initials/Date**
- **No medications taken throughout study.**
  - **Staff Initials/Date**

- **End of form. Submit to DF/Net.**

- **Page #**
Purpose:
All medication(s) that are used by the participant during the study [(including the protocol-defined screening period)], other than study product, must be documented on this form. This includes, but is not limited to, prescription medications, non-prescription (i.e., over-the-counter) medications, preventive medications and treatments (e.g., allergy shots, flu shots, and other vaccinations), herbal preparations, vitamin supplements, and naturopathic preparations.

General Instructions:
When to fax this form:
• once the participant has enrolled in the study;
• when pages have been updated or additional Log pages have been completed (only fax updated or new pages);
• when the participant has completed study participation; and/or
• when instructed by SCHARP.

Item-specific Instructions:

<table>
<thead>
<tr>
<th>Page #</th>
<th>Number pages sequentially throughout the study, starting with 01. Do not repeat page numbers. Do not renumber any Concomitant Medications Log pages after faxing, unless instructed by DF/Net.</th>
</tr>
</thead>
<tbody>
<tr>
<td>No medications taken at Screening/Enrollment</td>
<td>Mark this box if no medications were taken by the participant from Screening through the Enrollment visit. This box should only be marked on Page 01.</td>
</tr>
<tr>
<td>No medications taken throughout study</td>
<td>Mark this box at the Termination visit if no medications were taken by the participant throughout the entire study.</td>
</tr>
<tr>
<td>Medication Name</td>
<td>Record generic name of medication. For combination generic medications, record the first three main active ingredients, if applicable.</td>
</tr>
<tr>
<td>Indication</td>
<td>For health supplements, such as multivitamins, record “general health.” For preventive medications, record “prevention of [insert condition]” (e.g., for flu shot, record “prevention of influenza”).</td>
</tr>
<tr>
<td>Date Started</td>
<td>If the participant is unable to recall the exact date, obtain participant’s best estimate. At a minimum, the year is required.</td>
</tr>
<tr>
<td>Date Stopped</td>
<td>At the participant’s Termination visit, the “Date Stopped” must be recorded for each medication OR the “Continuing at end of study” box must be marked. At a minimum, the month and year are required.</td>
</tr>
<tr>
<td>Frequency</td>
<td>Below is a list of common frequency abbreviations: prn: as needed qd: every day tid: three times daily qhs: at bedtime once: one time bid: twice daily qid: four times daily other specify: alternative dosing schedules</td>
</tr>
<tr>
<td>Dose/Units</td>
<td>If the participant does not know the dose or units, draw a single line through the blank response box and initial and date. For prescription combination medications, record the dosage of first three main active ingredients. For multivitamin tablets or liquids, record number of tablets or liquid measurement (e.g., one tablespoon).</td>
</tr>
<tr>
<td>Route</td>
<td>Below is a list of common route abbreviations: PO: oral IV: intravenous IHL: inhaled REC: rectal other, specify: IM: intramuscular TOP: topical VAG: vaginal SC: subcutaneous alternative routes</td>
</tr>
</tbody>
</table>
### Demographics

1. What is your date of birth?  
   
2. What was your sex at birth?  
   - [ ] male  
   - [x] female

3. Are you currently married?  
   - [ ] yes  
   - [ ] no

4. Do you currently live with your partner?  
   - [ ] yes  
   - [ ] no

5. What is your highest level of education?  
   - [ ] no schooling  
   - [ ] primary school, not complete  
   - [ ] primary school, complete  
   - [ ] secondary school, not complete  
   - [ ] secondary school, complete  
   - [ ] attended college or university

6. Do you consider yourself to be Latino/a or of Hispanic origin?  
   - [ ] yes  
   - [ ] no

7. What is your race?  
   Mark all that apply.  
   - [ ] American Indian or Alaska Native  
   - [ ] Asian  
   - [ ] Black or African American  
   - [ ] Native Hawaiian or other Pacific Islander  
   - [ ] White  
   - [ ] Other, specify: __________________________

8. Do you earn an income of your own?  
   - [ ] yes  
   - [ ] no  
   **If no, go to item 9.**

   8a. How do you earn income?  
   Mark all that apply.  
   - [ ] formal employment  
   - [ ] self-employment  
   - [ ] other

9. How do you identify your gender?  
   Mark all that apply.  
   - [ ] male  
   - [ ] female  
   - [ ] transgender male (female to male)  
   - [ ] additional category, specify: __________________________
   - [ ] decline to state
Purpose:
This form is interviewer-administered and is used to collect participant’s demographic and socioeconomic information.

General Instructions:
This form is faxed to DataFax only if the participant enrolls in the study. This form is completed at the Screening Visit. Read each item aloud, except item 2, and record the participant's response.

Item-specific Instructions:

<table>
<thead>
<tr>
<th>Item</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Item 3</td>
<td>Mark “yes” if the participant is in a legally-binding marriage and has obtained a marriage certificate.</td>
</tr>
<tr>
<td>Item 5</td>
<td>If the participant attended or completed a post-secondary diploma or certificate program mark “attended college or university.”</td>
</tr>
<tr>
<td>Item 6</td>
<td>This item is based on self-definition. Per NIH policy, Latina or Hispanic includes a person of Cuban, Mexican, Puerto Rican, South or Central American, or other Spanish culture or origin, regardless of race.</td>
</tr>
<tr>
<td>Item 7</td>
<td>Record the participant’s race based on self-definition. In the case of mixed race, mark all that apply and/or “other” and indicate the mixed race background. Per NIH policy, Latino/a is considered an ethnic group and not a race and should not be entered in item 7f.</td>
</tr>
<tr>
<td>Item 9</td>
<td>This item must be self-reported by the participant. Site staff is encouraged to document in chart notes if the participant during study participation prefers to be referred to by a specific pronoun or gender.</td>
</tr>
</tbody>
</table>
Eligibility Criteria

1. Does this participant meet all eligibility criteria?  
   yes no If no, go to item 2

   1a. Obtain signature
       ____________________________
       Signature of Principal Investigator (or designee)   Date

   1b. Obtain signature
       ____________________________
       Signature of second staff member verifying eligibility   Date

2. Was the participant enrolled?  
   yes no If yes, end of form.

3. Why was the participant not enrolled?  
   participant did not complete all screening procedures End of form.
   eligible but declined enrollment End of form.
   not eligible

4. Reason(s) for ineligibility Mark all that apply.
   4a. participant < 18 or > 45 years old
   4b. plans for relocation/travel
   4c. participant is pregnant or planning to become pregnant within the next 3 months
   4d. participant is breastfeeding
   4e. participant unwilling to refrain from receptive sexual activity
   4f. participant has enrolled in another research study in the last 60 days
   4g. diagnosed with PID, RTI, or STI, which has not resolved
   4h. PEP or PrEP exposure in the last 6 months
   4i. participant is HIV-positive
   4j. participant declines effective method of contraception
   4k. participant has a grade 1 or higher pelvic exam finding
   4l. participant does not meet laboratory eligibility criteria. Specify or provide test results:
   4m. participant does not meet other clinical eligibility criteria
   4n. other reason, including investigator decision. Specify:

Comments: ____________________________

Version 1.0, 01-APR-15
**Purpose:**
This form is used to document participant eligibility for enrollment in this study or reasons for participant ineligibility.

**General Instructions:**
Complete this form for each participant screened for this study. Complete and fax this form once it is determined whether the participant will enroll in the study. If not enrolled, this is the only form that is faxed for the participant.

If the participant has a second screening attempt, update this form with data from the second screening attempt and refax. Do not complete a new form for the second attempt.

**Item-specific Instructions:**

<table>
<thead>
<tr>
<th>Items 1a and 1b</th>
<th>Local site Standard Operating Procedures (SOPs) must specify staff members designated to affirm eligibility.</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Item 3</strong></td>
<td>Mark “participant did not complete all screening procedures” when a participant begins the screening process and is eligible, but does not return to the clinic to complete screening procedures within the 45-day screening window.</td>
</tr>
<tr>
<td><strong>Item 4</strong></td>
<td>Mark all reasons for participant ineligibility. Refer to the Eligibility Checklist for the Screening and Enrollment Visit. If the reason for ineligibility is not listed, mark the “other reason, including investigator decision” box and specify ineligibility reason on the line provided.</td>
</tr>
</tbody>
</table>
Enrollment

1. Date the participant marked or signed the consent form for study participation:

2. Did the participant consent to:
   2a. long-term specimen storage and future testing?
   2b. participate in Extra Samples Group (rectal fluid for PK collection)?

3. Plasma for archive:

4. Randomization number assigned:

5. Randomization date and time:

6. Date and time vaginal ring inserted:

7. Was a Baseline CASI questionnaire completed at this visit?

8. Were there any problems or QC issues related to the administration or completion of the CASI questionnaire?

8a. Describe:

If no, end of form.
Purpose:
This form is used to document a participant’s study enrollment/randomization. This form is completed at the Enrollment Visit for the randomized participant.

General Instructions:
Fax this form to DF/Net only if the participant is enrolled (that is, if she has been randomized).

Item-specific Instructions:

<table>
<thead>
<tr>
<th>Item</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Item 2</td>
<td>Consent for long-term specimen storage or participation in the PK Subset can be changed if the participant changes her consent decision after enrollment. Update as needed if the participant changes her consent during the study.</td>
</tr>
<tr>
<td>Item 3</td>
<td>If the specimen for some reason is not stored, mark “not stored” and record the reason on the line provided.</td>
</tr>
<tr>
<td>Item 4</td>
<td>This item must match the randomization number provided within the randomization assignment confirmation email from FSTRF web-based system.</td>
</tr>
<tr>
<td>Item 5</td>
<td>These items must match the ‘date assigned’ and ‘time assigned’ recorded for this randomized participant within the randomization assignment confirmation email from the FSTRF web-based system.</td>
</tr>
<tr>
<td>Items 7–8</td>
<td>The Baseline CASI questionnaire is required at the Enrollment Visit. If it was not done, mark item 8 “yes” and provide a brief explanation in item 8a.</td>
</tr>
</tbody>
</table>
Follow-up CASI Tracking

1. Was a CASI questionnaire administered at this visit?
   - Yes [ ]
   - No [ ]

2. Were there any problems or issues related to the administration or completion of the questionnaire?
   - Yes [ ]
   - No [ ]

   2a. Describe:

   __________________________________________________________
   __________________________________________________________
   __________________________________________________________
   __________________________________________________________

Comments:

________________________________________________________________________
________________________________________________________________________
________________________________________________________________________
________________________________________________________________________
Purpose:
This form is used to document participant completion of the Computer-assisted Self Interview (CASI) computerized questionnaires during follow-up.

General Instructions:
Complete this form at the Day 7, Day 14, Day 21, Day 28 and Day 35/Final Clinic Visit. Also complete this form at the participant’s early termination visit.

Item-specific Instructions:

| Item 2a | If there were any unusual details related to the CASI questionnaire administration or completion, describe them on the line provided. |
Follow-up Visit Summary

1. Since the last visit, has the participant taken HIV medication for post-exposure prophylaxis (PEP) against HIV?
   - yes
   - no
   If yes, record on Concomitant Medications Log; complete Product Hold/Discontinuation Log.

2. Since the last visit, has the participant used oral or topical medicine for pre-exposure prophylaxis (PrEP) against HIV?
   - yes
   - no
   If no, go to item 3.

   2a. Was oral or topical PrEP used?
       - oral
       - topical
       - both
       Record on Concomitant Medications Log; complete Product Hold/Discontinuation Log.

3. hCG for pregnancy
   - Not done/Not collected
     Go to item 4.
   - negative
   - positive
     If positive, complete the Pregnancy Report and History. Complete Clinical Product Hold/Discontinuation Log, if applicable.

4. Were any new Adverse Experience Logs completed for this visit?
   - yes
   - no

5. Were any new Clinical Product Hold/Discontinuation Logs completed for this visit?
   - yes
   - no

6. Is this an interim visit?
   - yes
   - no
   If no, go to statement above item 7.

   6a. Reason for interim visit
       Mark all that apply.
       - AE report or follow-up
       - return of product or need new product
       - other, specify: ______________________

   6b. Which forms, besides this form and the log forms, were newly completed for this interim visit? Mark “None” or all that apply.
       - None
       - Pelvic Exam
       - Ring Collection and Insertion
       - STI Test Results
       - Pharmacokinetics
       - HIV Results
       - Specimen Storage
       - Physical Exam
       - Safety Laboratory Results
       - other, specify: ______________________

Item 7 for Day 35/Final Clinic Visit or early termination visit. For all other visits, end of form.

7. Was an in-depth interview completed?
   - yes
   - no

Comments: ______________________

Version 1.0, 01-APR-15
Purpose:
This form is used to summarize information from each participant follow-up study visit (including interim visits).

General Instructions:
This form is completed for each scheduled visit. This form is also completed for interim visits/contacts where a new form (other than the Follow-up Visit Summary) is completed. Note that there is no Interim Visit form for this study—instead, this form is completed to document interim visits.

Item-specific Instructions:

<table>
<thead>
<tr>
<th>Item</th>
<th>Description</th>
</tr>
</thead>
</table>
| **Visit Code** | • Record the visit code assigned to the visit. For required visits, the Visit Code will end in 0 (XX.0). If the visit is an interim visit/contact, use an interim code for the Visit Code. Start with the Visit Code of the last required visit and add “1” to the right of the decimal point for each interim visit conducted.  
  • If procedures for a required visit are split over 2 or more days, and all days are within the same visit window, assign all forms completed for the split visit the same Visit Code (ending in .0).  
  • For more information on visit code assignments, please refer to Section 12 of the SSP. |
| **Item 1** | If the participant has taken post-exposure prophylaxis (PEP) since her last visit, mark “yes” and update the Concomitant Medications (CM) Log. |
| **Item 2** | Record if the participant has used oral or topical medicine for pre-exposure prophylaxis (PrEP) against HIV and indicate whether oral or topical PrEP was used. If either or both were used, update the Concomitant Medications (CM) Log. |
| **Item 4** | Mark “yes” if at least one Adverse Experience (AE) Log was newly completed for this visit (Visit Code in item 10 of the AE Log is the same as the Visit Code recorded on this form). |
| **Item 5** | Mark “yes” if at least one Clinical Product Hold/Discontinuation (PH) Log was newly completed for this visit (Visit Code in item 1 of the PH Log is the same as the Visit Code recorded on this form). |
| **Item 6b** | Mark the newly completed forms (in addition to this form) that are being submitted for the interim visit/contact. If “other, specify” is marked, record the form acronyms in the space provided. |
| **Item 7** | Indicate whether an IDI was completed at the participant’s Day 35/final clinic visit or early termination visit. At all other visits, leave this item blank. |
## HIV Results

<table>
<thead>
<tr>
<th>Participant ID</th>
<th>Specimen Collection Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>Site Number</td>
<td>Participant Number</td>
</tr>
</tbody>
</table>

### HIV Results

1. HIV

<table>
<thead>
<tr>
<th>Not done/Not collected</th>
<th>negative</th>
<th>positive</th>
<th>indeterminate</th>
</tr>
</thead>
</table>

*If any are positive or indeterminate, complete HIV Confirmatory Results form and complete Clinical Product Hold/Discontinuation Log.*

**Comments:**

- 
- 
- 
- 

Version 1.0, 01-APR-15
Purpose:
This form is used to document the participant's HIV results.

General Instructions:
Record test results on this form as they become available. Fax this form into DF/Net DataFax once results for all collected specimens are recorded on the form. Complete this form at Day 35/Final Clinic Visit and if indicated during follow-up.

Item-specific Instructions:

<table>
<thead>
<tr>
<th>Specimen Collection Date:</th>
<th>Record the date that the first specimen was collected (NOT the date results were reported or recorded on the form). A complete date is required.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Not done/Not collected:</td>
<td>Mark this box in the event that a specimen was not collected or if the specimen was collected, but a result is not available due to specimen loss or damage. Record the reason why the result is not available in the Comments.</td>
</tr>
</tbody>
</table>
### HIV Confirmatory Results

**SAMPLE 1**

1. **HIV Confirmation Test**
   - **Western Blot**
     - Not done
     - negative
     - positive
     - indeterminate
   - **Multispot**
     - Not done
     - negative
     - HIV-1 reactive
     - HIV-2 reactive
     - HIV-1/2 undifferentiated
     - invalid
   - **4th Generation HIV EIA**
     - Not done
     - negative/ non-reactive
     - positive/ reactive
   - **HIV RNA PCR**
     - Not done
     - >
     - =
     - <

```
1d1. RNA PCR kit lower limit of detection
20
40
```

2. **Final HIV Status**
   - HIV-uninfected
   - HIV-infected
   - pending

**Comments:**

________________________________________________________________________
________________________________________________________________________
________________________________________________________________________
________________________________________________________________________

---

**Version 1.0, 01-APR-15**
**Purpose:**
This form is used to document results from local lab confirmatory HIV testing once a participant has a positive or indeterminate EIA test result.

**General Instructions:**
Complete this form for each visit where the participant has a positive or indeterminate EIA test result.

**Item-specific Instructions:**

<table>
<thead>
<tr>
<th>Visit Code</th>
<th>The visit code recorded on this form should be the same visit code recorded on the Laboratory Results form documenting the positive or indeterminate EIA test result.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Specimen Collection Date</td>
<td>Record the date the specimen was collected (NOT the date results were reported or recorded on the form). The Specimen Collection Date should be the same date as the collection date of the plasma for HIV seroconversion confirmation.</td>
</tr>
<tr>
<td>Item 1</td>
<td>If confirmatory test is used, but is not listed, specify which test is used in the comments section of this form and contact the Lab Center for further guidance.</td>
</tr>
<tr>
<td>Items 1a, 1b, 1c, and 1d</td>
<td>If the result is “negative,” “indeterminate,” or “invalid,” consult the Lab Center.</td>
</tr>
<tr>
<td>Item 2</td>
<td>Once a participant’s HIV status has been determined, record the final HIV status. Once all results are available, if the final HIV status is not clearly negative or clearly positive, mark “pending.” If additional testing is done to determine final status, record details in Comments.</td>
</tr>
</tbody>
</table>
MTN 027 DF/Net 027

Visit Code

Missed Visit (MV)

MTN 027

Participant ID

Site Number - Participant Number - Chk

Form Completion Date

dd MMMM yy

Missed Visit

1. Target Visit Date

2. Reason visit was missed. *Mark only one.*

   - 2a. unable to contact participant
   - 2b. unable to schedule appointment(s) within allowable window
   - 2c. participant refused visit
   - 2d. participant incarcerated
   - 2e. participant admitted to a health care facility
   - 2f. participant withdrew from study  *Complete Termination form.*
   - 2g. participant deceased  *Complete Termination form. Complete Adverse Experience Log.*
   - 2h. other, specify: ____________________________________________

3. Steps taken to address the missed visit (corrective action plan):

   ____________________________________________
   ____________________________________________
   ____________________________________________

Comments:

   ____________________________________________
   ____________________________________________
   ____________________________________________

Version 1.0, 01-APR-15
Purpose:
Complete this form whenever an enrolled participant misses a required visit according to the visit window outlined in the protocol or Study-specific Procedures (SSP).

General Instructions:
• If the QC Report indicates that a visit is overdue, confirm that the visit was missed before completing a Missed Visit form. Fax this form when it is determined that a visit has been missed and cannot be completed within the visit window. Record the Visit Code of the visit that was missed. Record the date that the form was completed. This will not necessarily be the date of the missed visit.

Item-specific Instructions:

<table>
<thead>
<tr>
<th>Item 1</th>
<th>Record the target date of the visit. A complete date is required.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Item 2</td>
<td>Record the reason the participant missed the visit.</td>
</tr>
</tbody>
</table>
## Protocol Deviation Log

1. Site awareness date:  
   - dd  
   - MMM  
   - yy  

2. Deviation date:  
   - dd  
   - MMM  
   - yy  

3. Has or will this deviation be reported to local IRB/EC?  
   - yes  
   - no  

4. Has or will this deviation be reported to DAIDS as a critical event?  
   - yes  
   - no  

5. Type of deviation:  
   - deviation code (See back of form for code listing.)

6. Description of deviation:  
   - 
   - 
   - 

7. Plans and/or action taken to address the deviation:  
   - 
   - 
   - 

8. Plans and/or action taken to prevent future occurrences of the deviation:  
   - 
   - 
   - 

9. Deviation reported by:  
   - staff code
**Purpose:**
This form documents and reports protocol deviations identified for study participants.

**General Instructions:**
Complete this form each time a protocol deviation is identified. Consult the MTN Regulatory Team (mtnregulatory@mtnstopshiv.org) and the Study Management Team if you are unsure if an event requires reporting as a deviation.

**Item-specific Instructions:**

<table>
<thead>
<tr>
<th>Page</th>
<th>Number pages sequentially for each participant, starting with 01. Do not re-assign page numbers if a form is marked for deletion.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Item 2</td>
<td>Record the date the event occurred (start date).</td>
</tr>
<tr>
<td>Item 5</td>
<td>Record the two-digit category code that best describes the type of deviation. Use “99” (other) if none of the listed categories match. Describe the specifics of the deviation in item 6.</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>01</td>
<td>Inappropriate enrollment: The participant enrolled and not all eligibility requirements were met.</td>
</tr>
<tr>
<td>02</td>
<td>Failure to follow trial randomization or blinding procedures: Include instances where randomization procedures were not followed by site staff, or product blinding procedures were not followed by pharmacy staff.</td>
</tr>
<tr>
<td>03</td>
<td>Study product management deviation: The site staff did not instruct the participant to hold, permanently discontinue, or resume study product use per protocol requirements.</td>
</tr>
<tr>
<td>04</td>
<td>Study product dispensing error: The wrong study product was dispensed to a participant, or study product was dispensed to a participant on product hold. Do not include any information related to study product assignment (product codes) on this form. Pharmacy staff must follow up with the MTN Pharmacist separately.</td>
</tr>
<tr>
<td>05</td>
<td>Study product use/non-use deviation: Participant did not use the study product (including refusals) or used it incorrectly (i.e., not in accordance with protocol requirements).</td>
</tr>
<tr>
<td>06</td>
<td>Study product sharing: Participant has shared study product with another person or study participant.</td>
</tr>
<tr>
<td>07</td>
<td>Study product not returned: Study product was not returned by the participant per protocol requirements.</td>
</tr>
<tr>
<td>08</td>
<td>Conduct of non-protocol procedure: A clinical or administrative procedure was performed that was not specified in the protocol, and was not covered under local standard of care practice.</td>
</tr>
<tr>
<td>09</td>
<td>Improper AE/EAE follow-up: Use when an AE or EAE is not followed per protocol. For example, a clinical finding/lab result is not re-assessed as outlined in the protocol.</td>
</tr>
<tr>
<td>10</td>
<td>Unreported AE: Site staff become aware of an AE, but do not report it per protocol requirements.</td>
</tr>
<tr>
<td>11</td>
<td>Unreported EAE: Site staff become aware of an EAE, but do not report it per protocol and DAIDS EAE Manual requirements.</td>
</tr>
<tr>
<td>12</td>
<td>Breach of confidentiality: Include potential and actual cases where participant confidentiality is breached. For example, a staff member puts a participant’s name on a case report form.</td>
</tr>
<tr>
<td>13</td>
<td>Physical assessment deviation: Include missed or incomplete physical/pelvic/rectal exam assessments.</td>
</tr>
<tr>
<td>14</td>
<td>Lab assessment deviation: Include missed, or incomplete lab specimen collection.</td>
</tr>
<tr>
<td>15</td>
<td>Mishandled lab specimen: Include errors in the labeling, physical handling, processing, testing, storage, or shipment of collected lab specimens.</td>
</tr>
<tr>
<td>16</td>
<td>Staff performing duties that they are not qualified to perform: Use for any instance when any study procedure, including clinical and administrative procedures, is completed by a staff member who is not adequately qualified AND delegated to perform the procedure.</td>
</tr>
<tr>
<td>17</td>
<td>Questionnaire administration deviation: A required questionnaire was not completed according to protocol requirements. Include instances where the wrong questionnaire was completed.</td>
</tr>
<tr>
<td>18</td>
<td>Counseling deviation: Protocol-required counseling was not done and/or not documented correctly.</td>
</tr>
<tr>
<td>19</td>
<td>Use of non-IRB/EC-approved materials: Include use of ANY study-related material that requires IRB or EC approval for use per site requirements.</td>
</tr>
<tr>
<td>20</td>
<td>Use of excluded concomitant medications, devices or non-study products</td>
</tr>
<tr>
<td>21</td>
<td>Informed consent process deviation: Examples include failure to accurately execute and/or document any part of the informed consent process.</td>
</tr>
<tr>
<td>22</td>
<td>Visit completed outside of window: Use when visit procedures for a visit are done within the wrong window or not in a designated visit window. For example, use if Visit 3.0 procedures are done in the Visit 4.0 window.</td>
</tr>
<tr>
<td>99</td>
<td>Other</td>
</tr>
</tbody>
</table>

| Item 6 | Briefly describe the specific details of the deviation. |
| Item 9 | Record staff code of the site staff person who completed the form. Sites will need to assign a four-digit staff code to each site staff person who will be completing this form. This list is created, maintained, and kept at the study site. |

**Version 1.0, 01-APR-15**
### Pelvic Exam

**1. Vaginal pH:**
- [ ] Not done
- [ ] If > 4.5, mark Positive
- [ ] Positive

**2. Pelvic exam assessment:**
- [ ] Not done
- [ ] Abnormal findings
- [ ] No abnormal findings
- [ ] End of form.

**2a. Abnormal findings. Mark all that apply:**

<table>
<thead>
<tr>
<th>VULVAR</th>
<th>VAGINAL</th>
<th>CERVICAL</th>
<th>GENERAL/OTHER</th>
</tr>
</thead>
<tbody>
<tr>
<td>Vulvar edema</td>
<td>Vaginal edema</td>
<td>Cervical edema and/or friability</td>
<td>Odor (vaginal)</td>
</tr>
<tr>
<td>Vulvar erythema</td>
<td>Vaginal erythema</td>
<td>Cervical erythema</td>
<td>Condyloma, specify location:</td>
</tr>
<tr>
<td>Vulvar rash</td>
<td>Vaginal masses (polyps, myomas, possible malignancy)</td>
<td>Cervical masses (polyps, myomas, possible malignancy)</td>
<td>Adnexal masses (based on bimanual exam; not pregnancy or infection-related)</td>
</tr>
<tr>
<td>Vulvar tenderness</td>
<td>Vaginal abrasions or lacerations</td>
<td>Cervical motion tenderness</td>
<td>Uterine masses (based on bimanual exam)</td>
</tr>
<tr>
<td>Bartholin’s or Skene’s gland abnormality</td>
<td>Vaginal tenderness</td>
<td>Cervical discharge</td>
<td>Uterine tenderness</td>
</tr>
<tr>
<td>Vulvar lesions</td>
<td>Abnormal vaginal discharge</td>
<td></td>
<td>Adnexal tenderness</td>
</tr>
<tr>
<td>Ulcer</td>
<td>slight moderate pooling</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Blister</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pustule</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Peeling</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ecchymosis</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**2b. Other abnormal findings, specify (include anatomical location):**

*Complete or update Pre-existing Conditions or Adverse Experience Log, as applicable.*

**3. Are any new pelvic finding AEs reported at this visit?**
- [ ] Yes
- [ ] No
- [ ] End of form.

**3a. AE Log page #(#s): Line through any unused boxes.**

---

*Version 1.0, 01-APR-15*

*Staff initials/Date*
**Purpose:**
This form is used to document the participant's pelvic exam assessment.

**General Instructions:**
Complete this form at Screening, Enrollment, at all follow-up study visits, and early termination visit (as applicable), and when a clinically indicated pelvic exam is performed during interim visits. Transcribe information from the Pelvic Exam Diagrams form (non-DataFax) onto this form for submission to DataFax.

**Item-specific Instructions:**

<table>
<thead>
<tr>
<th>Item 1</th>
<th>Vaginal fluid pH is required at Enrollment Visit, Day 3, Day 28, Day 29, Day 30, Day 31, and Day 35/Final Clinic Visit.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Item 2</td>
<td>Note that observation of any genital blood or bleeding is considered an abnormal finding, regardless of whether the blood is expected (menstrual blood, for example). If blood or bleeding is observed, mark “abnormal findings” and in item 2a, mark “observed blood or bleeding; describe” and describe on the lines provided.</td>
</tr>
</tbody>
</table>

| Item 2a | • Mark the box to the left of each abnormal finding observed. In general, for abnormal findings reported as adverse events on an AE Log, use text from item 2a as AE descriptive text finding (this does not apply to observances of blood or bleeding).  
• **Observed blood or bleeding; describe:** If blood or bleeding is observed, mark this item and in the space provided, briefly describe the color, amount, and location of the blood/bleeding. If known, specify if the blood was menstrual or non-menstrual. Assess the blood/bleeding for AE reporting purposes. Please refer to Study-specific Procedures (SSP) manual section section 8 for AE reporting guidance for observed bleeding.  
• Each instance of observed blood/bleeding should be assessed for severity grade per the applicable rows of the Division of AIDS Table for Grading the Severity of Adult and Pediatric Adverse Events Addendum 1: Female Genital Grading Table for Use in Microbicide Studies (FGGT). Refer to SSP manual section 8 for more information/guidance as needed. |

| Item 2b | If an observed abnormal finding is not listed, mark “other abnormal findings, specify” and describe the abnormal finding on the line provided, including anatomical location. |
External Genitalia

Legend for Vagina/Cervix
1. Anterior vagina, distal half
2. Anterior vagina, proximal half
3. Anterior fornix
4. Cervical trunk, anterior
5. Left lateral vagina, distal half
6. Left lateral vagina, proximal half
7. Left lateral fornix
8. Cervical trunk, left lateral
9. Right lateral vagina, distal half
10. Right lateral vagina, proximal half
11. Right lateral fornix
12. Cervical trunk, right lateral
13. Posterior vagina, distal half
14. Posterior vagina, proximal half
15. Posterior fornix
16. Cervical trunk, post
17. Cervical face

Speculum Type (screening only)
- Pederson
- Graves
- Cusco

Speculum Size (screening only)
- Small
- Medium
- Large

no normal variants or abnormal findings observed
**Purpose:**
This form is used to document all variants of normal and all abnormal findings observed during study pelvic exams (screening through termination/study exit).

**General Instructions:**
This form is completed at the Screening Visit, the Enrollment Visit, at all scheduled study visits, and whenever a pelvic exam is clinically indicated during the study. This is a non-DataFax form and should not be faxed to DF/Net DataFax. Transcribe information onto the appropriate Pelvic Exam DataFax form for submission to DataFax and store this form in the participant’s chart notes.

**Item-specific Instructions:**

<table>
<thead>
<tr>
<th>Findings</th>
<th>All variants of normal (normal findings) and all abnormal findings must be documented on this form. Variants of normal need only be recorded on this form, and not on any of the Pelvic Exam DataFax forms. The following findings are considered normal variants:</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>• anatomic variants</td>
</tr>
<tr>
<td></td>
<td>• gland openings</td>
</tr>
<tr>
<td></td>
<td>• Nabothian cysts</td>
</tr>
<tr>
<td></td>
<td>• mucus retention cysts</td>
</tr>
<tr>
<td></td>
<td>• Gartner’s duct cysts</td>
</tr>
<tr>
<td></td>
<td>• blood vessel changes other than disruption</td>
</tr>
<tr>
<td></td>
<td>• skin tags</td>
</tr>
<tr>
<td></td>
<td>• scars</td>
</tr>
<tr>
<td></td>
<td>• cervical ectopy</td>
</tr>
</tbody>
</table>

If there are no variants of normal or abnormal findings observed mark the “no normal variants or abnormal findings observed” box.

<table>
<thead>
<tr>
<th>Documenting findings on the cervix:</th>
<th>If helpful, draw the os in the center of the diagram labeled “Cervix” (lower right corner).</th>
</tr>
</thead>
</table>
Pelvic Exam Ring Assessment

1. Was the vaginal ring present in the vagina at the start of the exam?  
   - Yes  
   - No  
   **If no, go to item 3.**

2. Was the vaginal ring removed during the exam?  
   - Yes  
   - No  
   **If no, end of form.**
   
   2a. If yes, how long was the vaginal ring removed from the vagina?  
      - Hours:  
      - Minutes: 

3. Was the vaginal ring rinsed prior to reinsertion?  
   - Yes  
   - No  
   **Not reinserted**
   
   3a. Specify reason ring not reinserted:  

   **If yes or no, end of form.**
Purpose:
The purpose of this form is to document presence/absence of the vaginal ring during pelvic exams.

General Instructions:
This form is completed for pelvic exams performed during the vaginal ring use period (post enrollment up through Day 28 Visit).
Clinical Product Hold/Discontinuation Log

1. Date and visit code when study product hold was initiated:

2. Why is study product being held?  Mark only one per page:
   - positive HIV test result
   - adverse experience
   - pregnancy
   - use of prohibited medications
   - breastfeeding
   - report of PEP use for HIV exposure
   - report of PrEP use for HIV exposure
   - other, specify:

3. Date of last study product use:

4. Was the participant instructed to resume study product use?
   - yes, Date:
   - no—hold continuing for another reason, Date:
   - no—early termination, Date:
   - no—hold continuing at the Day 28 visit, Date:
   - no—permanently discontinued, Date:

Comments:

Version 1.0, 01-APR-15
Purpose:
This log is used to document temporary clinical holds and clinical permanent discontinuations of study product use as instructed by study site staff. This log is completed each time a participant is instructed by study staff to temporarily stop (hold) or permanently discontinue study product use. If, at the same visit, a product hold/discontinuation is initiated for more than one reason, complete one Clinical Product Hold/Discontinuation Log page for each reason. The same visit code should be used on each Log page.
Do not complete this log in cases where a participant has decided on his/her own to stop using study product. This information will be documented on the Ring Collection and Insertion form.

Item-specific Instructions:

<table>
<thead>
<tr>
<th>Page</th>
<th>Item 2</th>
<th>Item 3</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Note that participant decline or refusal of study product is not documented as a product hold. Do not record this as a reason in “other, specify.”</td>
<td>Record the last date the participant used study product. Use a best estimate if the actual date cannot be determined. <strong>Note:</strong> <em>Do not wait for information about product resumption or permanent discontinuation to fax the form—fax this form to DF/Net DataFax as soon as items 1 through 3 have been completed. Refax the page once item 4 has been completed.</em></td>
</tr>
<tr>
<td></td>
<td>Item 4</td>
<td>If “no—hold for another reason” is marked, record the date that the participant would have been instructed to resume study product use based on resolution of the reason indicated in item 2. If “no—permanently discontinued” is marked, record the date the reason in item 2 met criteria for permanent discontinuation. <strong>Note:</strong> <em>This date could fall anytime between enrollment through and including the date of termination.</em> If “no-hold continuing at the Day 28 visit” is marked, record the date the Day 28 visit was completed. If the Day 28 visit was missed, record the target date of the Day 28 visit. If the reason for the hold later meets criteria for permanent discontinuation between the Day 28 visit and the date of termination, update the response to “no-permanently discontinued” and record the date the reason first met criteria for permanent discontinuation.</td>
</tr>
</tbody>
</table>
### Pharmacokinetics Specimens—Days 1, 2, 3, 7, 14, 21, 29, 30, 31, 35

1. **Last menstrual period:**
   - [□] None
   - [ ] Not done/Not collected

   **Start Date:**
   - [□] dd
   - [□] MMM
   - [□] yy

   **Stop Date:**
   - [□] dd
   - [□] MMM
   - [□] yy

   **Stored**
   - [□]

   **Not Stored**
   - [□]

   **If not stored, specify:**

2. **Single time-point blood draw:**
   - [□] Stored
   - [□] Not Stored

   **If not stored, specify:**

3. **Single time-point vaginal fluid for PK:**
   - [□] Stored
   - [□] Not Stored

   **If not stored, specify:**

   **Was blood visible on swab?**
   - [□] Yes
   - [□] No

   **3a. Number of vaginal swabs collected:**
   - [□]

**Comments:**

---

**Version 1.0, 01-APR-15**
Purpose:
This form is used to document collection and timing of collection of pharmacokinetic (PK) laboratory specimens.

General Instructions:
Complete this form at Days 1, 2, 3, 7, 14, 21, 29, 30, 31, and 35.

Item-specific Instructions:

<table>
<thead>
<tr>
<th>Item 1</th>
<th>If the participant has not had a period within the last 30 days, mark “none.”</th>
</tr>
</thead>
<tbody>
<tr>
<td>Not done/</td>
<td>Mark this box in the event that a specimen was not collected or not required.</td>
</tr>
<tr>
<td>Not collected</td>
<td></td>
</tr>
<tr>
<td>Stored/</td>
<td>Mark “stored” for specimens that are collected and sent to the lab for processing. If specimens</td>
</tr>
<tr>
<td>Not Stored</td>
<td>are not stored by the lab, mark “not stored” and record the reason why on the line provided.</td>
</tr>
</tbody>
</table>
## Pharmacokinetics Specimens—Day 28

### 1. Last menstrual period:
- [ ] None

<table>
<thead>
<tr>
<th>Specimen</th>
<th>Start Date</th>
<th>Stop Date</th>
<th>If not stored, specify:</th>
<th>Stored</th>
<th>Not Stored</th>
</tr>
</thead>
<tbody>
<tr>
<td>Blood</td>
<td>dd MMM yy</td>
<td>dd MMM yy</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>0-hour blood draw</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1-hour blood draw</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2-hour blood draw</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>4-hour blood draw</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>6-hour blood draw</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Vaginal Fluid</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>0-hour vaginal fluid for PK</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1-hour vaginal fluid for PK</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2-hour vaginal fluid for PK</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>4-hour vaginal fluid for PK</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>6-hour vaginal fluid for PK</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Other</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Rectal fluid for PK</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cervical biopsy for PK</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cervical biopsy for PD</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Comments:**

**Version 1.0, 01-APR-15**
**Purpose:**
This form is used to document collection and timing of collection of pharmacokinetic (PK) laboratory specimens.

**General Instructions:**
Complete this form at Day 28.

**Item-specific Instructions:**

<table>
<thead>
<tr>
<th>Item 1</th>
<th>If the participant has not had a period within the last 30 days, mark “none.”</th>
</tr>
</thead>
<tbody>
<tr>
<td>Not done/Not collected</td>
<td>Mark this box in the event that a specimen was not collected or not required.</td>
</tr>
<tr>
<td>Stored/Not Stored</td>
<td>Mark “stored” for specimens that are collected and sent to the lab for processing. If specimens are not stored by the lab, mark “not stored” and record the reason why on the line provided.</td>
</tr>
<tr>
<td>Item 14</td>
<td>This item should be completed by the Pittsburgh site only. A cervical biopsy for PD is not required at the Alabama CRS and can be marked &quot;not done/not collected&quot;.</td>
</tr>
<tr>
<td>Specimen</td>
<td>Stored</td>
</tr>
<tr>
<td>----------------------------------</td>
<td>--------</td>
</tr>
<tr>
<td>Blood</td>
<td></td>
</tr>
<tr>
<td>1-hour blood draw:</td>
<td></td>
</tr>
<tr>
<td>2-hour blood draw:</td>
<td></td>
</tr>
<tr>
<td>4-hour blood draw:</td>
<td></td>
</tr>
<tr>
<td>6-hour blood draw:</td>
<td></td>
</tr>
<tr>
<td>Vaginal fluid</td>
<td></td>
</tr>
<tr>
<td>0-hour vaginal fluid for PK:</td>
<td></td>
</tr>
<tr>
<td>1-hour vaginal fluid for PK:</td>
<td></td>
</tr>
<tr>
<td>2-hour vaginal fluid for PK:</td>
<td></td>
</tr>
<tr>
<td>4-hour vaginal fluid for PK:</td>
<td></td>
</tr>
<tr>
<td>6-hour vaginal fluid for PK:</td>
<td></td>
</tr>
<tr>
<td>Other</td>
<td></td>
</tr>
<tr>
<td>Rectal fluid for PK:</td>
<td></td>
</tr>
</tbody>
</table>

Comments:
Purpose:
This form is used to document collection and timing of collection of pharmacokinetic (PK) laboratory specimens.

General Instructions:
Complete this form at the Enrollment visit.

Item-specific Instructions:

<table>
<thead>
<tr>
<th>Item 1</th>
<th>If the participant has not had a period within the last 30 days, mark “none.”</th>
</tr>
</thead>
<tbody>
<tr>
<td>Not done/ Not collected</td>
<td>Mark this box in the event that a specimen was not collected or not required.</td>
</tr>
<tr>
<td>Stored/ Not Stored</td>
<td>Mark “stored” for specimens that are collected and sent to the lab for processing. If specimens are not stored by the lab, mark “not stored” and record the reason why on the line provided.</td>
</tr>
</tbody>
</table>
### Pregnancy Outcome

If Outcome Number recorded is 2 or greater, go to item 2. 

**Page 1 of 2**

1. How many pregnancy outcomes resulted from this reported pregnancy?  

2. Outcome Date  

3. Place of delivery/outcome  
   - home  
   - unknown  
   - hospital  
   - other, specify: ___________________________

4. Specify outcome. Mark only one.  

   **Items 4a–4f:** If the pregnancy or outcome was associated with maternal complications or symptoms that would otherwise be reported as an AE, report these on an AE Log. Complete an EAE Reporting form, if applicable.  

   - [ ] 4a. full term live birth (= 37 weeks)  
   - [ ] 4b. premature term live birth (< 37 weeks)  
   - [ ] 4c. stillbirth/intrauterine fetal demise (= 20 weeks)  
   - [ ] 4d. spontaneous abortion (< 20 weeks)  
   - [ ] 4e. ectopic pregnancy  
   - [ ] 4f. therapeutic/elective abortion  
   - [ ] 4g. other, specify: ___________________________

5. Provide a brief narrative of the circumstances: ___________________________

6. Were there any complications related to the pregnancy outcome?  
   - [ ] yes  
   - [ ] no  
   if no, go to item 7 on page 2.

   **6a. Delivery-related complications**  
   Mark “none” or all that apply. 
   - [ ] 6a1. none  
   - [ ] 6a2. intrapartum hemorrhage  
   - [ ] 6a3. postpartum hemorrhage  
   - [ ] 6a4. non-reassuring fetal status  
   - [ ] 6a5. chorioamnionitis  
   - [ ] 6a6. other, specify: ___________________________

   **6b. Non-delivery-related complications**  
   Mark “none” or all that apply. 
   - [ ] 6b1. none  
   - [ ] 6b2. hypertensive disorders of pregnancy  
   - [ ] 6b3. gestational diabetes  
   - [ ] 6b4. other, specify: ___________________________
**Purpose**
This form is used to report pregnancy outcome information for a pregnancy reported post-enrollment. Complete this form when information about a pregnancy outcome becomes available to study staff or when it is determined that pregnancy outcome is unobtainable.

**General Instructions:**
A Pregnancy Outcome form is required for each Pregnancy Report and History form that is completed for a participant.

**Item-specific Instructions:**

<table>
<thead>
<tr>
<th>Visit Code</th>
<th>Record the visit code of the participant’s corresponding Pregnancy Report and History form.</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Outcome Number</strong></td>
<td>A pregnancy outcome can be an infant or fetus. The conception of twins, for example, will result in reporting of two outcomes. For a pregnancy resulting in one outcome, record “1” here. For a pregnancy with multiple outcomes, record the outcome number corresponding to the outcome data recorded on the form.</td>
</tr>
<tr>
<td><strong>Outcome unobtainable</strong></td>
<td>If it is determined that an outcome is unobtainable (i.e., the participant refuses further contact), mark the “Outcome unobtainable” box at the top of the page and fax both pages of this form to DF/Net.</td>
</tr>
<tr>
<td><strong>Item 1</strong></td>
<td>If the pregnancy results in two or more outcomes, complete a Pregnancy Outcome form for each outcome. Each Pregnancy Outcome form will have the same visit code, but different outcome numbers (for example, one Pregnancy Outcome form will have an outcome number =1 and the second form will have an outcome number =2, and so on).</td>
</tr>
<tr>
<td><strong>Item 4</strong></td>
<td>If the outcome is spontaneous fetal death, still birth, spontaneous abortion, therapeutic/elective abortion, or ectopic pregnancy, the outcome itself is not an adverse experience (AE). If a therapeutic/elective abortion is performed due to a pregnancy complication, the pregnancy complication should be reported on an Adverse Experience (AE) Log, if prior to termination, with “procedure/surgery” marked under item 7, “Treatment.” If there are any maternal complications as a result of the pregnancy outcome, refer to the protocol, Study-specific Procedures (SSP) manual, and Manual for Expedited Reporting of Adverse Events to DAIDS, Version 2 for guidance on AE and expedited AE reporting requirements.</td>
</tr>
<tr>
<td><strong>Item 4a1</strong></td>
<td>“Operative vaginal” delivery includes delivery with forceps and/or vacuum.</td>
</tr>
<tr>
<td><strong>Item 5</strong></td>
<td>Include information on medical conditions associated with the outcome, including early contractions, rupture of membranes, and cramping, along with actions taken as a result of these conditions.</td>
</tr>
</tbody>
</table>
### Pregnancy Outcome Page 2 of 2

7. Were any fetal/infant congenital anomalies identified? Yes ☐ No ☐ Unknown ☐ If no or unknown, go to the statement above item 8.

7a. Congenital anomalies identified. Mark all that apply. **Complete AE Log and EAE Reporting form.**

- [ ] central nervous system, cranio-facial
- [ ] central nervous system, spinal
- [ ] cardiovascular
- [ ] renal
- [ ] gastrointestinal
- [ ] pulmonary
- [ ] musculoskeletal/extremities
- [ ] physical defect
- [ ] skin
- [ ] genitourinary
- [ ] chromosomal
- [ ] cranio-facial (structural)
- [ ] hematologic
- [ ] infectious
- [ ] endocrine/metabolic
- [ ] other

7b. Describe the congenital anomaly/defect: ____________________________________________

**Complete items 8–13 for live births only. Otherwise, end of form.**

8. Infant gender

- [ ] male
- [ ] female

9. Infant birth weight

- [ ] . kg
- [ ] unavailable OR [ ]

10. Infant birth length

- [ ] . cm
- [ ] unavailable OR [ ]

11. Infant birth head circumference

- [ ] . cm
- [ ] unavailable OR [ ]

12. Infant birth abdominal circumference

- [ ] . cm
- [ ] unavailable OR [ ]

13. Infant gestational age by examination

- [ ] weeks
- [ ] days
- [ ] unavailable OR [ ] If unavailable, end of form.

13a. Method used to determine gestational age

- [ ] Ballard
- [ ] Dubowitz
- [ ] other, specify: ____________________________________________

---

Version 1.0, 01-APR-15
### Item-specific Instructions:

<table>
<thead>
<tr>
<th>Visit Code</th>
<th>Record the visit code that is present on page 1 of this form.</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>No data recorded on this page:</strong></td>
<td>This box should only be marked if the “outcome unobtainable” box is marked on page 1. This box must only be marked if all items on the page are left blank.</td>
</tr>
<tr>
<td><strong>Outcome Number</strong></td>
<td>Record the outcome number that is present on page 1 of this form.</td>
</tr>
<tr>
<td><strong>Item 7a</strong></td>
<td>If a woman on study has a baby with a congenital anomaly, report the event on an Adverse Experience (AE) Log, if prior to termination. On the AE Log, record “Congenital Anomaly in Offspring” on item 1, record the Outcome Date as the Onset Date, and record the specific anomaly in Comments. Also submit an Expedited Adverse Event (EAE) Reporting form.</td>
</tr>
<tr>
<td><strong>Items 9–12</strong></td>
<td>Record the information as documented in medical records. If no medical record documentation of the information is available, complete this item based on participant report. Mark “unavailable” if no medical record documentation is available and the participant does not know the information.</td>
</tr>
<tr>
<td><strong>Item 13</strong></td>
<td>Record the infant’s gestational age at birth. If the infant’s gestational age is determined using the Ballard method, please record “0” in the “days” box. Mark “unavailable” if no medical record documentation of the infant’s gestational age is available.</td>
</tr>
</tbody>
</table>
**Pregnancy Report and History (PR)**

<table>
<thead>
<tr>
<th><strong>1</strong></th>
<th>First day of last menstrual period</th>
</tr>
</thead>
<tbody>
<tr>
<td>dd</td>
<td>MMM</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>2</strong></th>
<th>Estimated date of delivery</th>
</tr>
</thead>
<tbody>
<tr>
<td>dd</td>
<td>MMM</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>3</strong></th>
<th>What information was used to estimate the date of delivery?</th>
</tr>
</thead>
<tbody>
<tr>
<td>3a.</td>
<td>last menstrual period</td>
</tr>
<tr>
<td>3b.</td>
<td>initial ultrasound &lt; 20 weeks</td>
</tr>
<tr>
<td>3c.</td>
<td>initial ultrasound &gt;= 20 weeks</td>
</tr>
<tr>
<td>3d.</td>
<td>physical examination</td>
</tr>
<tr>
<td>3e.</td>
<td>conception date by assisted reproduction</td>
</tr>
<tr>
<td>3f.</td>
<td>other, specify: ______________________________</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>4</strong></th>
<th>Has the participant ever been pregnant before?</th>
</tr>
</thead>
<tbody>
<tr>
<td>yes</td>
<td>no</td>
</tr>
<tr>
<td>4a.</td>
<td>Is this the participant’s first pregnancy since enrollment in this study?</td>
</tr>
<tr>
<td>yes</td>
<td>no</td>
</tr>
<tr>
<td>4b.</td>
<td>Number of full-term live births (&gt; 37 weeks)</td>
</tr>
<tr>
<td>4c.</td>
<td>Number of premature live births (&lt; 37 weeks)</td>
</tr>
<tr>
<td>4d.</td>
<td>Number of spontaneous fetal deaths and/or still births (&gt; 20 weeks)</td>
</tr>
<tr>
<td>4e.</td>
<td>Number of spontaneous abortions (&lt; 20 weeks)</td>
</tr>
<tr>
<td>4f.</td>
<td>Number of therapeutic/elective abortions</td>
</tr>
<tr>
<td>4g.</td>
<td>Number of ectopic pregnancies</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>5</strong></th>
<th>Does the participant have a history of pregnancy complications or fetal/infant congenital anomalies before study enrollment?</th>
</tr>
</thead>
<tbody>
<tr>
<td>yes</td>
<td>no</td>
</tr>
<tr>
<td>5a.</td>
<td>If yes, specify: ____________________________________________</td>
</tr>
</tbody>
</table>
**General Instructions:**
Complete this form when reporting a pregnancy of a study participant post-enrollment through termination. Record the visit code of the visit at which study staff became aware that the participant is/was pregnant.

**Item-specific Instructions:**

<table>
<thead>
<tr>
<th>Item 1</th>
<th>A complete date is required. Record best estimate if date not known.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Item 2</td>
<td>A complete date is required.</td>
</tr>
</tbody>
</table>
### Participant Receipt

**Instruction:** Do not assign a new Participant ID. Record the Participant ID assigned by the original study site.

1. Name of receiving study site
   
2. Name of transferring study site
   
3. Date informed consent signed at receiving study site
   
4. Did participant provide informed consent for specimen storage at receiving study site?
   
4a. Date informed consent signed at receiving study site

Comments:

---

**Version 1.0, 01-APR-15**
General Instructions:

- Complete this form when a transferred participant has provided informed consent at the receiving study clinic/site.
- The **Participant Receipt** form is completed by the receiving site (the site at which the participant will be continuing his or her study visits).
- For more information on Participant Transfer and Receipt, refer to the protocol, Study-specific Procedures (SSP), and/or Manual of Operations (MOP).

Item-specific Instructions:

<table>
<thead>
<tr>
<th><strong>Participant ID</strong></th>
<th>Do not assign a new Participant ID. Record the Participant ID assigned by the original study site.</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Item 3</strong></td>
<td>A complete date is required.</td>
</tr>
<tr>
<td><strong>Item 4a</strong></td>
<td>A complete date is required.</td>
</tr>
<tr>
<td>Participant ID</td>
<td>Site Number</td>
</tr>
<tr>
<td>----------------</td>
<td>-------------</td>
</tr>
</tbody>
</table>

**Pre-existing Conditions**

<table>
<thead>
<tr>
<th>Condition</th>
<th>Onset Date</th>
<th>Staff Initials/Date</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>MMM</td>
<td>yy</td>
</tr>
</tbody>
</table>

**Comments**

<table>
<thead>
<tr>
<th>Ongoing at Enrolment?</th>
<th>Severity Grade</th>
</tr>
</thead>
<tbody>
<tr>
<td>yes</td>
<td></td>
</tr>
<tr>
<td>no</td>
<td></td>
</tr>
</tbody>
</table>

**Note:** Number pages sequentially (01, 02, 03) for each participant.

End of form. Submit to DF/Net.
Purpose:
The Pre-existing Conditions form serves as the “starting point” or baseline from which study clinicians must determine whether conditions identified during follow-up are adverse events (AEs).

General Instructions:
• At the Screening Visit, record relevant baseline medical history. This includes conditions and symptoms reported by the participant during the baseline medical/menstrual history as well as any conditions identified via pelvic exam, physical exam, or laboratory testing. This includes, but is not limited to, history of hospitalizations, surgeries, allergies, any condition that required prescription or chronic medication (that is, more than 2 weeks in duration), and acute conditions ongoing at screening and/or that occur between screening and enrollment.
• At the Enrollment Visit, review and update as needed.
• Do record pre-existing conditions if identified during follow-up. Add a chart note to explain why the PRE entry was added after Enrollment.

Item-specific Instructions:

<p>| Page | Number pages sequentially throughout the study, starting with “01.” Do not repeat page numbers. Do not renumber any Pre-existing Conditions pages after faxing, unless instructed by DF/Net. |
| Condition | Whenever possible, provide a diagnosis instead of listing a cluster of symptoms. If no diagnosis is identified, each symptom must be recorded as a separate entry on the Pre-existing Conditions form. If an abnormal lab value is reported, record the lab assay with the direction (i.e., increased or decreased) of the abnormality. For example, “decreased hematocrit” or “increased ALT.” |
| Onset Date | If the participant is unable to recall the date, obtain participant’s best estimate. At a minimum, the year is required. |
| Comments | This field is optional. Use it to record any additional relevant information about the condition, including any associated signs/symptoms. |
| Ongoing at Enrollment? | Mark “yes” for chronic conditions, as well as any other conditions, ongoing at the Enrollment Visit. If a condition resolves or increases in severity or frequency after the Enrollment Visit, document this in chart notes and/or another document other than this form. |
| Severity Grade | For each condition, grade the severity according to the Division of AIDS (DAIDS) Table for Grading the Severity of Adult and Pediatric Adverse Events and the DAIDS Female Genital Grading Table for Use in Microbicide Studies (as appropriate). If a condition is not gradable, mark “not gradable”. Review and update as needed for conditions ongoing at the Enrollment Visit. |</p>
<table>
<thead>
<tr>
<th>Participant ID</th>
<th>Form Completion Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>Site Number</td>
<td>Participant Number</td>
</tr>
</tbody>
</table>

**Participant Transfer**

1. Name of transferring study site

2. Name of receiving study site

3. Visit Code of last completed contact with participant

4. Date participant records were sent to receiving study site

Comments:
General Instructions:

- Complete this form when a participant is transferring to another study clinic/site. The Participant Transfer form is completed by the transferring site (the site that the participant is leaving).
  For more information on Participant Transfer and Receipt, refer to the protocol, Study-specific Procedures (SSP), and/or Manual of Operations (MOP).

Item-specific Instructions:

| Item 4 | A complete date is required. |
### Physical Exam

#### Vital Signs

<table>
<thead>
<tr>
<th></th>
<th>Not Required</th>
<th>Height: cm</th>
<th></th>
<th>BP: mmHg</th>
<th>Pulse: beats per minute</th>
<th>Respirations: breaths per minute</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>3</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

#### FINDINGS:

- **Items 8–16 may be omitted after Enrollment.**

<table>
<thead>
<tr>
<th></th>
<th>Not Done</th>
<th>Normal</th>
<th>Abnormal</th>
<th>Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>7</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>8</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>9</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>10</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>11</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>12</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>13</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>14</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>15</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>16</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>17</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Record abnormal findings on Pre-existing Conditions or Adverse Experience Log form as applicable.

**Comments:**

---

**Version 1.0, 01-APR-15**
**Purpose:**
This form is used to document the participant’s vital signs and physical exam findings.

**General Instructions:**
Complete this form at the Screening, Enrollment, and all follow-up study visits. If abnormal findings are found, for items 7–17, transcribe the information onto the Pre-existing Conditions or Adverse Experience form(s).

**Item-specific Instructions:**

<table>
<thead>
<tr>
<th><strong>Vital Signs</strong></th>
<th>Use leading zeros as applicable.</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Item 1</strong></td>
<td>This item is required at Screening and Enrollment only.</td>
</tr>
<tr>
<td><strong>Items 7–16</strong></td>
<td>For each organ system or body part evaluated, indicate whether the findings were normal or abnormal. If abnormal, describe the findings in Notes. If not evaluated, mark “not done” and record the reason in Notes. Normal findings may also be described in Notes, but is not required.</td>
</tr>
<tr>
<td><strong>Item 17</strong></td>
<td>If no other abnormal findings are identified, mark “not done.”</td>
</tr>
</tbody>
</table>
### Ring Adherence

1. **Date and visit code this form was last completed for this participant?**
   - [ ] Yes
   - [ ] No
   - **If no, end of form.**

2. **Since this form was last completed, has the ring been out at any time?**
   - [ ] Yes
   - [ ] No
   - **If 6 or more, add Comment after completing items 3a–3e.**

3. **For each instance the vaginal ring was out, complete the information below on when the ring was out, how long it was out, and why it was out? Ring removals due to scheduled pelvic exams should not be recorded on this form.**

<table>
<thead>
<tr>
<th>Date ring out</th>
<th>Duration ring was out</th>
<th>Removal/Expulsion code</th>
</tr>
</thead>
<tbody>
<tr>
<td>dd-MMM-yyyy</td>
<td>days hours minutes</td>
<td></td>
</tr>
</tbody>
</table>

   a. [ ]
   b. [ ]
   c. [ ]
   d. [ ]
   e. [ ]

4. **Has the vaginal ring stayed in place for at least the past 8 hours prior to this visit?**

   - [ ] Yes
   - [ ] No
   - **If no, specify details in the Comments section.**

**Comments:**

**Version 1.0, 01-APR-15**
**Purpose:**
This form is used to collect participant-reported information on ring use (adherence). This includes all instances where the participant reports the ring has not been used, regardless of reason for non-use.

**General Instructions:**
Complete this form at the Day 1, 2, 3, 7, 14, 21 and 28 visits only. This form is required at each of these visits, even if the participant has been on product hold. Do not complete this form at Interim Visits.

**Item-specific Instructions:**

<table>
<thead>
<tr>
<th>Item 1</th>
<th>Record the date of enrollment and visit code “02.0” the first time this form is completed for each participant.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Item 2</td>
<td>Per participant report, if the ring has been out (not inserted) for any amount of time since the last time the form was completed for the participant, mark &quot;yes&quot; and continue with the form. If the participant reports the study vaginal ring has been in continuously since the last time this form was completed, mark &quot;no&quot; and end the form.</td>
</tr>
<tr>
<td>Item 2a</td>
<td>Record how many separate times the participant reports the ring has been out since the last time the form was completed.</td>
</tr>
</tbody>
</table>

**Items 3a–3e:**

| Items 3a–3e: Removal/Expulsion Codes | Select from the codes below and record the code that best describes why the vaginal ring was taken out or came out on its own. |

**Item 4:**
If the participant reports the ring has not been in place during the previous 8 hours prior to the visit, provide details in the comments section and include the time and duration of the outage(s), if possible.

**REASONS RING REMOVED BY PARTICIPANT OR CLINICIAN**

<table>
<thead>
<tr>
<th>Hygienic or Physical Reasons</th>
<th>Social or Sexual Reasons</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Code</strong></td>
<td><strong>Description</strong></td>
</tr>
<tr>
<td>10 Discomfort/symptoms: Ring caused discomfort/ participant experienced genital or other symptoms</td>
<td>20 Partner ring knowledge: Did not want husband or primary sex partner to know about ring</td>
</tr>
<tr>
<td>11 Ring falling out: Ring was partially falling out</td>
<td>21 Partner concerns/objections: Husband or any sex partner did not like the ring and/or wanted her to remove/stop using the ring</td>
</tr>
<tr>
<td>12 Ring placement: Didn’t feel the ring was correctly placed</td>
<td>22 Family concerns/objections: Family member (other than husband/primary sex partner) did not like the ring and/or wanted her to remove/stop using the ring</td>
</tr>
<tr>
<td>13 Ring presence: Wanted to look at the ring or see if the ring was still in place</td>
<td>23 Friend or peer concerns/objections: Friend or peer did not like the ring and/or wanted her to remove/stop using the ring</td>
</tr>
<tr>
<td>14 Menses/Bleeding: Had or was expecting menses/ any type of genital bleeding or spotting</td>
<td>24 Removal for sex: Participant or partner did not want to have vaginal sex with the ring in place</td>
</tr>
<tr>
<td>15 Cleaned ring: Removed ring to clean it</td>
<td>25 Discomfort during sex: The ring feeling uncomfortable or painful during vaginal sex</td>
</tr>
<tr>
<td>16 Cleaned vagina: Removed ring to clean vagina</td>
<td>26 Partner felt ring during sex: The sex partner feeling the ring during sex</td>
</tr>
</tbody>
</table>

**Study-related or Procedural Reasons**

<table>
<thead>
<tr>
<th>Code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>30</td>
<td>Product hold: Participant placed on product hold</td>
</tr>
<tr>
<td>31</td>
<td>Product permanently discontinued: Participant permanently discontinued from product</td>
</tr>
<tr>
<td>32</td>
<td>Procedure: Ring removed for clinical procedure (e.g., IUCD insertion) that was not conducted at a regularly scheduled study visit</td>
</tr>
<tr>
<td>33</td>
<td>Inserted new ring: Ring removed to insert new ring between study visits or at an interim visit</td>
</tr>
<tr>
<td>34</td>
<td>Missed visit: Participant removed ring due to missed scheduled visit</td>
</tr>
</tbody>
</table>

**REASONS RING CAME OUT ON ITS OWN**

<table>
<thead>
<tr>
<th>Code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>40</td>
<td>Urination</td>
</tr>
<tr>
<td>41</td>
<td>Bowel movement: Having a bowel movement</td>
</tr>
<tr>
<td>42</td>
<td>Sex: Having sex or just finished sex</td>
</tr>
<tr>
<td>43</td>
<td>Physical activity: Physical activity (other than sex), including lifting heavy objects</td>
</tr>
<tr>
<td>44</td>
<td>Body position: Was squatting or sitting or changing body position (i.e., move from lying down to standing up)</td>
</tr>
<tr>
<td>45</td>
<td>Menses: Had her menses</td>
</tr>
</tbody>
</table>

**Version 1.0, 01-APR-15**
<table>
<thead>
<tr>
<th>Participant ID</th>
<th>Visit Code</th>
</tr>
</thead>
<tbody>
<tr>
<td>Site Number</td>
<td>Participant Number</td>
</tr>
</tbody>
</table>

### Ring Collection and Insertion

1. Did the participant have a ring in place at the start of the visit?  
   - Yes  
   - No  
   
   **If yes, go to item 2.**

1a. When was the ring last in place?  
   - dd  
   - MMM  
   - yy  
   
   OR  
   - Not applicable (ring not in place since last visit)

2. Number of **used** rings collected:  
   - None  
   - 1  
   
   **If “1,” go to item 3.**

2a. If none, specify reason: 

3. Number of **new** rings dispensed to participant:  
   - None  
   - 1  
   
   **If “1,” go to item 4.**

3a. Reason ring not dispensed:  
   - participant on clinical hold  
   - participant has been permanently discontinued from product  
   - participant declined study ring; specify:  
   - early termination  
   - Day 28 ring removal visit  
   - Other, specify: 

4. Was a new ring inserted at this visit?  
   - Yes  
   - No  
   
   **If no, go to item 5.**

4a. Time new ring was inserted:  
   - hh  
   - mm  
   (24-hour clock)

4b. Who inserted the new ring?  
   - Participant  
   - Study staff

5. Was a ring in place at the end of the visit?  
   - Yes  
   - No  
   
   **If yes, end of form.**

5a. Reason ring not in place at end of visit:  
   - participant declined to have ring inserted  
   - participant had to leave before ring could be inserted  
   - Other, specify: 

---

**Version 1.0, 01-APR-15**

---

Staff Initials/Date
Purpose:
This form is used to document rings that are inserted and collected for each participant for the duration of the study.

General Instructions:
• Complete this form at the Day 28 visit, and at early termination visit, as applicable. Complete at interim visits as needed.
• If the participant has been permanently discontinued from study product, this form is not required to be completed at visits following the permanent discontinuation.

Item-specific Instructions:

<table>
<thead>
<tr>
<th>Item</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Item 1a</td>
<td>If the vaginal ring was not in place at the start of the visit, record the date the vaginal ring was last in place over the past month. If the participant is unable to recall the exact date, obtain the participant's best estimate. At a minimum, the month and year are required. If the ring was not in place at any time since this form was last completed, mark &quot;not applicable.&quot;</td>
</tr>
<tr>
<td>Item 2a</td>
<td>If no rings were collected (returned), specify the reason why (for example, participant forgot, or participant had no dispensed rings to return).</td>
</tr>
<tr>
<td>Item 3</td>
<td>Only document ring(s) dispensed and given to the participant.</td>
</tr>
<tr>
<td>Item 3a</td>
<td>If participant declined to have a ring dispensed to her, record a brief reason for her decline on the line provided. If the reason for her decline is due to or associated with an adverse event, document the adverse event on an Adverse Experience (AE) Log and note in the AE Log comments that the participant declined the ring because of the AE.</td>
</tr>
</tbody>
</table>
### Social Impact Log

**Instructions:** Fax this form to DataFax whenever a new social impact is recorded or information on this form is updated. Fax only pages with new entries or revisions.

1. Concisely describe social impact:
   - 
   - 

2. Onset date:  
   - dd
   - MMM
   - yy

3. Reported at visit:  
   - 

4. Social impact code:  
   - See back for codes and definitions.
   - 4a. Did this involve physical harm to the participant?  
     - Yes
     - No
   - 4b. Did this involve physical or other harm to participant’s child(ren)?  
     - Yes
     - No

5. What impact did this situation have on the participant’s quality of life?  
   - Minimal disturbance
   - Moderate disturbance; no significant impact
   - Major disturbance with significant impact

6. Describe what was done by staff and participant to address social impact:
   - 6a. Participant:  
     - 
     - 
   - 6b. Staff:  
     - 
     - 

7. Record current status:  
   - Unresolved
   - Unresolved at end of study
   - Unable to resolve; no further action taken
   - Resolved

   Closure Date:  
   - dd
   - MMM
   - yy

---

**Version 1.0, 01-APR-15**

---

Note: Number pages sequentially (01, 02, 03) for each participant.
Purpose:
Complete this form when recording the occurrence, update, and resolution of adverse social impacts reported by participants at any time during the study.

General Instructions:
This form should be completed only when a participant has a negative experience associated with study participation.

Item-specific Instructions:

<table>
<thead>
<tr>
<th>Page</th>
<th>Number pages sequentially throughout the study, starting with 01. Do not repeat page numbers/Do not renumber any Social Impact Log pages after faxing, unless instructed by DF/Net.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Item 2</td>
<td>Record the date the negative experience first started. At minimum, a month and year are required.</td>
</tr>
<tr>
<td>Item 4</td>
<td>Use the Code List below to code the social impact. Use leading zeros when needed.</td>
</tr>
</tbody>
</table>
| Item 5 | • Minimal impact—no or little interference with usual social and/or functional activities  
• Moderate impact—greater than minimal interference with usual social and/or functional activities  
• Severe impact—inability to perform usual social and/or functional activities |
| Item 7 | This item may be updated at subsequent follow-up visits. |

<table>
<thead>
<tr>
<th>Code</th>
<th>Definition</th>
</tr>
</thead>
</table>
| 01   | Personal Relationships  
Had negative experiences with family (excluding partner) |
| 02   | Partner Relationships  
Had negative experiences with significant other, spouse, or sex partner |
| 03   | Personal Relationships—Other  
Had negative experiences with friends, neighbors or other community members |
| 04   | Travel/Immigration  
Had problems obtaining formal permission to travel to or enter another country, such as being denied a visa, or had a problem with immigration/naturalization |
| 05   | Employment  
Been turned down for a job, lost a job, study visits interfering with work/work performance or experienced other problems at work |
| 06   | Education  
Been turned down by an educational program, told to leave an educational program, study visits interfering with school attendance/performace, or experienced other problems at school |
| 07   | Medical/Dental  
Been refused medical or dental treatment, or treated negatively by a health care provider |
| 08   | Housing  
Had trouble getting or keeping housing, had negative experience with landlord, or had other problems related to housing |
| 09   | Other  
Had other problems not covered in the codes above |
## Safety Laboratory Results

<table>
<thead>
<tr>
<th>Component</th>
<th>Value</th>
<th>Severity Grade</th>
<th>AE Log Page</th>
<th>Not reportable as an AE</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>HEMOGRAM</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1a. Hemoglobin</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1b. Hematocrit</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1c. MCV</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1d. Platelets</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1e. WBC</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>DIFFERENTIAL</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1f. Neutrophils</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1g. Lymphocytes</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1h. Monocytes</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1i. Eosinophils</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1j. Basophils</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
**Purpose:**
This form is used to provide data on the participant's baseline and follow-up laboratory test results.

**General Instructions:**
Use this form to report the hematology, differential, and liver and renal function test results as they become available. Do not fax the form to DF/Net until all results are available and the participant has enrolled in the study.

**Item-specific Instructions:**

<table>
<thead>
<tr>
<th>Item-specific Instructions</th>
<th>Details</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Initial Specimen Collection Date</strong></td>
<td>Record the date that the first specimen was collected (NOT the date the results were reported or recorded on the form) for this visit. A complete date is required.</td>
</tr>
<tr>
<td><strong>Alternate Collection Date</strong></td>
<td>This date is to be completed ONLY if the specimen was collected on a date after the Initial Specimen Collection Date. A specimen collected for the same visit but on a different date should be recorded on the same form.</td>
</tr>
<tr>
<td><strong>Not done/Not collected</strong></td>
<td>Mark this box in the event that a specimen was not collected or if the specimen was collected, but a result is not available due to specimen loss or damage. Record the reason why the result is not available in Comments on page 2.</td>
</tr>
<tr>
<td><strong>Visit Code</strong></td>
<td>Record the visit code assigned to this visit. Refer to the Study-Specific Procedures (SSP) Manual for more specific information on assigning visit codes.</td>
</tr>
<tr>
<td><strong>Repeat Testing</strong></td>
<td>If any or all of the lab tests listed on this form are repeated (re-drawn) between the Screening and Enrollment Visit, document the repeated results on the same SLR form assigned Visit Code 1.0. Line through the original result(s), record the new result(s) and the Alternate Collection Date for each repeat test result.</td>
</tr>
</tbody>
</table>
| **Results Reporting** | • Results should be documented on the form using the units present on the source laboratory results document. If the units present on the form do not match your source results report, contact the MTN-027 Management Team. Note that the following units are equivalent: IU/L = U/L, l/l x 100 = %, 10^9/L = 10^5/mm^3 = 10^5/μL
For creatinine, only record the result in the units listed on the source document.
• If the site lab does not report results to the same level of precision allowed on the form, record a zero (0) in the box(es) to the right of the decimal point. For example, a lab-reported hematocrit value of 30% would be recorded as 30.0%.
• It may be necessary to round the result reported by the lab up or down to the level of precision allowed on the form. For example, a lab-reported hemoglobin value of 11.05 g/dL would be recorded as 11.1 g/dL. A lab-reported hemoglobin value of 11.04 g/dL would be recorded as 11.0 g/dL.
• If the site lab does not produce test results in the units used on this form, first perform the conversion, then round the converted result if necessary. |
| **Severity Grade** | • If any values meet the criteria for severity grade 1 or greater, according to the appropriate DAIDS Table for Grading the Severity of Adult and Pediatric Adverse Events, record the grade in the appropriate box next to the result. If value is below Grade 1, leave the severity grade box blank.
• Always compare the severity grade range to the value that was recorded on the form (not the lab-reported value).
• When working with calculated severity grade ranges (e.g., 1.1–1.5 times the site lab upper limit of normal), the calculated range may have more significant digits than the lab result.
• Treat all missing digits in the lab value as zeros.
• If the lab value falls between two calculated severity grade ranges, assign it the higher grade.
• At Screening/Enrollment, record any Grade 1 or higher lab values on the Pre-existing Conditions form. |
### Safety Laboratory Results

#### 2. SERUM CHEMISTRIES

<table>
<thead>
<tr>
<th>Test</th>
<th>Alternate Collection Date</th>
<th>Severity Grade If applicable</th>
<th>AE Log Page #</th>
<th>Not reportable as an AE</th>
</tr>
</thead>
<tbody>
<tr>
<td>2a. AST (SGOT)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2b. ALT (SGPT)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2c. Creatinine</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2c1. Calculated creatinine clearance</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

#### 3. DIPSTICK URINALYSIS TESTS

<table>
<thead>
<tr>
<th>Test</th>
<th>Alternate Collection Date</th>
<th>Severity Grade If applicable</th>
<th>AE Log Page #</th>
<th>Not reportable as an AE</th>
</tr>
</thead>
<tbody>
<tr>
<td>3a. Leukocyte esterase (LE)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>3b. Nitrites</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>3c. Protein</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>3d. Glucose</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Comments:**

_________________________________________________________________________

_________________________________________________________________________

_________________________________________________________________________

Version 2.0, 01-MAY-15
Purpose:
This form is used to provide data on the participant’s baseline and follow-up laboratory test results.

General Instructions:
Use this form to report the hematology, differential, and liver and renal function test results as they become available. Do not fax the form to DF/Net until all results are available and the participant has enrolled in the study.

Item-specific Instructions:

<table>
<thead>
<tr>
<th>Item</th>
<th>Instructions</th>
</tr>
</thead>
<tbody>
<tr>
<td>Alternate Collection Date</td>
<td>This date is to be completed ONLY if the specimen was collected on a date after the Initial Specimen Collection Date. A specimen collected for the same visit but on a different date should be recorded on the same form.</td>
</tr>
<tr>
<td>Not done/Not collected</td>
<td>Mark this box in the event that a specimen was not collected or if the specimen was collected, but a result is not available due to specimen loss or damage. Record the reason why the result is not available in Comments on page 2.</td>
</tr>
<tr>
<td>Visit Code</td>
<td>Record the visit code assigned to this visit. Refer to the Study-Specific Procedures (SSP) Manual for more specific information on assigning visit codes.</td>
</tr>
<tr>
<td>Repeat Testing</td>
<td>If any or all of the lab tests listed on this form are repeated (re-drawn) between the Screening and Enrollment Visit, document the repeated results on the same SLR form assigned Visit Code 1.0. Line through the original result(s), record the new result(s) and the Alternate Collection Date for each repeat test result.</td>
</tr>
<tr>
<td>Item 2c1</td>
<td>When calculating the participant’s creatinine clearance use the age and weight of the participant at the time the blood specimen is drawn. If the participant was not weighed at the visit when the blood specimen was drawn, but was weighed at a previous visit (within the allowable window for creatinine clearance per the SSP Manual), record the weight from the previous visit. Also, record in the “Alternative Collection Date” boxes the date of the previous visit when the participant was weighed. If the participant has a creatinine value but cannot have her creatinine clearance calculated (due to missing weight data), line through the response boxes and initial and date.</td>
</tr>
<tr>
<td>Item 3</td>
<td>If a dipstick urinalysis was done, but a given result was not reported, mark the “not done” box.</td>
</tr>
<tr>
<td>Items 3a-3b</td>
<td>If the result is negative or trace, mark the ‘negative’ box. If the result is 1+ or greater, mark the ‘positive’ box.</td>
</tr>
<tr>
<td>Item 3d</td>
<td>Grade the severity of the urine glucose value according to the “Proteinuria, random collection” row of the DAIDS Table for Grading the Severity of Adult and Pediatric Adverse Events.</td>
</tr>
</tbody>
</table>
Participant ID

Initial Specimen Collection Date

Specimen Storage

Not done/Not collected

1. Vaginal smear for gram stain

Alternate Collection Date

Not done/Not collected

2. Quantitative vaginal culture

Alternate Collection Date

Not done/Not collected

3. Vaginal swab for biomarkers:

3a. Was blood visible on the swab?

Yes

No

Alternate Collection Date

Not done/Not collected

4. Cervical cytobrush

Alternate Collection Date

Not done/Not collected

5. Used vaginal ring

Alternate Collection Date

Collection Time

(24-hour clock)

Reason not stored

Comments:

Version 1.0, 01-APR-15
**Purpose:**
This form is used to document collection and storage of vaginal and cervical specimens by the local site laboratory.

**General Instructions:**
Complete this form at Enrollment, Day 3, Day 28 and Day 35/Final Clinic Visit, as applicable.

**Item-specific Instructions:**

<table>
<thead>
<tr>
<th>Field</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Visit Code</td>
<td>Record the visit code assigned to this visit. Refer to the Study-Specific Procedures (SSP) Manual for more specific information on assigning visit codes.</td>
</tr>
<tr>
<td>Initial Specimen Collection Date</td>
<td>Record the date that the first specimen was collected (NOT the date the results were reported or recorded on the form) for this visit. A complete date is required.</td>
</tr>
<tr>
<td>Alternate Collection Date</td>
<td>This date is to be completed ONLY if the specimen was collected on a date after the Initial Specimen Collection Date. A specimen collected for the same visit but on a different date should be recorded on the same form. A complete date is required.</td>
</tr>
<tr>
<td>Not done/Not collected</td>
<td>Mark this box in the event that a specimen was not collected.</td>
</tr>
<tr>
<td>Stored/Not Stored</td>
<td>Mark “stored” for specimens that are collected and sent to the lab for processing. If specimens are not stored by the lab, mark “not stored” and record the reason why on the line provided.</td>
</tr>
</tbody>
</table>
## STI Test Results

### 1. VAGINAL WET PREP STUDIES

1a. Homogeneous vaginal discharge

1b. Whiff test

1c. Clue cells >= 20%

1d. *Trichomonas vaginalis*

1e. Buds and/or hyphae (yeast)

### 2. *Trichomonas* rapid test

### 3. *N. gonorrhea*

### 4. *C. trachomatis*

### 5. STI SEROLOGY

5a. Syphilis screening test

5a1. Syphilis titer:

5b. Syphilis confirmatory test

---

**Complete Adverse Experience Log if applicable.**

**Comments:**

---

**Version 1.0, 01-APR-15**
### Purpose:
This form is used to document Vaginal Wet Prep and STI Test Results by the local site laboratory.

### General Instructions:
Complete this form if indicated during follow-up.

### Item-specific Instructions:

<table>
<thead>
<tr>
<th>Item-specific Instructions</th>
<th>Details</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Initial Specimen Collection Date</strong></td>
<td>Record the date that the first specimen was collected (NOT the date the results were reported or recorded on the form) for this visit. A complete date is required.</td>
</tr>
<tr>
<td><strong>Alternate Collection Date</strong></td>
<td>This date is to be completed ONLY if the specimen was collected on a date after the Initial Specimen Collection Date. A specimen collected for the same visit but on a different date should be recorded on the same form.</td>
</tr>
<tr>
<td><strong>Not done/Not collected</strong></td>
<td>Mark this box in the event that a specimen was not collected or if the specimen was collected, but a result is not available due to specimen loss or damage. Record the reason why the result is not available in Comments.</td>
</tr>
<tr>
<td><strong>Visit Code</strong></td>
<td>Record the visit code assigned to this visit. Refer to the Study-Specific Procedures (SSP) Manual for more specific information on assigning visit codes.</td>
</tr>
<tr>
<td><strong>Items 1–4</strong></td>
<td>If a test result(s) recorded on this form indicates that the participant has a new (or increased severity) laboratory-confirmed infection or diagnosis, this infection/diagnosis must be recorded as an adverse experience on an Adverse Experience (AE) Log.</td>
</tr>
<tr>
<td><strong>Item 1</strong></td>
<td>If a vaginal wet prep was performed but not all assays were completed, mark &quot;Not done/Not collected&quot; for each uncompleted wet prep assay. If any and/or all assays were required but not completed, record the reason in Comments.</td>
</tr>
<tr>
<td><strong>Item 1a</strong></td>
<td>Mark “positive” if homogeneous vaginal discharge was observed.</td>
</tr>
<tr>
<td><strong>Item 1c</strong></td>
<td>Mark “positive” if 20% or more of the cells were clue cells.</td>
</tr>
<tr>
<td><strong>Item 1d</strong></td>
<td>Mark “positive” if trichomonads were observed.</td>
</tr>
<tr>
<td><strong>Item 1e</strong></td>
<td>Mark “positive” if yeast buds and/or hyphae were observed.</td>
</tr>
</tbody>
</table>
### Participant ID

<table>
<thead>
<tr>
<th>Site Number</th>
<th>Participant Number</th>
<th>Chk</th>
</tr>
</thead>
</table>

### Termination

**1**  
**Termination Date**  
**dd** MMMM **yy**  
Date the site determined that the participant was no longer in the study.

**2**  
Reason for termination. *Mark only one.*

- **2a.** Scheduled exit visit/end of study  
  > End of form.
- **2b.** Death
  
  - **2b1.** Date of death  
    | dd | MMMM | yy | OR | date unknown |
  
  - **2b2.** Cause of death  
    ____________________________  
    OR | cause unknown |
  
  - **2c.** Participant refused further participation, specify  
    ____________________________
  
  - **2d.** Participant unable to adhere to visit schedule
  
  - **2e.** Participant relocated, no follow-up planned
  
  - **2f.** Investigator decision, specify  
    ____________________________
  
  - **2g.** Unable to contact participant
  
  - **2h.** HIV infection  
    > If HIV-1 infection, complete HIV Results CRF. End of form.
  
  - **2i.** Inappropriate enrollment  
    > End of form.
  
  - **2j.** Invalid ID due to duplicate screening/enrollment  
    > End of form.
  
  - **2k.** Other, specify  
    ____________________________
  
  - **2l.** Early study closure  
    > End of form.
  
  - **2m.** Pregnancy

**3**  
Was termination associated with an adverse event?  
**yes**  
**no**  
**don't know**  
If no or don't know, end of form.

- **3a.** Record AE Log page number  
  | | OR | Specify ____________________________ |

**Comments:**

---

**Version 1.0, 01-APR-15**

---
Forms Instructions

Termination (TM)

General Instructions:
This form is completed for every enrolled participant at either the scheduled exit/end of study visit or when the participant is no longer participating in the study.

**Item-specific Instructions:**

<table>
<thead>
<tr>
<th>Item 1</th>
<th>A complete date is required.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Item 2</td>
<td>Mark only the primary reason for termination.</td>
</tr>
<tr>
<td>Item 2a</td>
<td>Only mark 2a if the participant completes the protocol-defined final visit.</td>
</tr>
<tr>
<td>Item 2b1</td>
<td>If date is recorded, at a minimum, the month and year are required.</td>
</tr>
<tr>
<td>Item 2l</td>
<td>Only mark 2l when instructed by SCHARP.</td>
</tr>
<tr>
<td>Item 3a</td>
<td>Record the page number of the <em>Adverse Experience Log</em> on which the AE was recorded. In situations where more than one AE is associated with termination, record the AE that most strongly influenced the decision to terminate. If termination is associated with a non-reportable AE, record the event on the “specify” line.</td>
</tr>
</tbody>
</table>